Document ID: chunk:federal_register_of_legislation:F2021L00353:reg:9:p2
Version: federal_register_of_legislation:F2021L00353
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 6541–7653

having facial paralysis.
(11)      taking a drug from the specified list of drugs for the treatment of cancer or autoimmune disease for at least the seven days before the clinical worsening of seborrhoeic dermatitis;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(12)      taking a drug which is associated in the individual with the clinical worsening of seborrhoeic dermatitis during drug therapy and either:
(a)           the improvement of seborrhoeic dermatitis within three months of discontinuing or tapering drug therapy; or
(b)          the worsening of seborrhoeic dermatitis on rechallenge with the same drug; and
where taking the drug continued for at least the seven days before the clinical worsening of seborrhoeic dermatitis;
(13)      wearing a surgical mask or face covering intended to provide protection from human-to-human respiratory virus transmission, for a cumulative period of at least 20 hours in the seven days before the clinical worsening of seborrhoeic dermatitis;
(14)      inability to obtain appropriate clinical management for seborrhoeic dermatitis.